{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:11:24Z","timestamp":1791090684089,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm & Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"abstract":"\n Overexpression of\n ABC<\/jats:styled-content>\n \u2010transporters including\n P<\/jats:styled-content>\n gp,\n MRP<\/jats:styled-content>\n 1, and\n BCRP<\/jats:styled-content>\n has been associated with multidrug resistance (\n MDR<\/jats:styled-content>\n ) in both human and canine oncology. Therapeutic interventions to reverse\n MDR<\/jats:styled-content>\n are limited, but include multidrug protocols and the temporary concomitant use of inhibitors of\n ABC<\/jats:styled-content>\n \u2010transporters. Recently, the use of tyrosine kinase inhibitors has been proposed to overcome\n MDR<\/jats:styled-content>\n in human oncology. One of the tyrosine kinase inhibitors, masitinib, is licensed for veterinary use in the treatment of canine mast cell tumors. Therefore, this study aimed to assess the potential of masitinib to revert\n MDR<\/jats:styled-content>\n in canine malignant lymphoma using an\n in vitro<\/jats:italic>\n model with canine lymphoid cell lines. Masitinib had a mild antiproliferative effect on lymphoid cells, inhibited\n P<\/jats:styled-content>\n gp function at concentrations equal to or exceeding 1\u00a0\u03bc\n m<\/jats:sc>\n and was able to reverse doxorubicin resistance. The current findings provide the rationale for a combined use of masitinib with doxorubicin in the treatment of dogs with doxorubicin\u2010resistant malignant lymphoma but await confirmation in clinical trials.\n <\/jats:p>","DOI":"10.1111\/jvp.12039","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T08:05:02Z","timestamp":1359619502000},"page":"583-587","source":"Crossref","is-referenced-by-count":31,"title":["Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of\n P<\/scp>\n \u2010glycoprotein"],"prefix":"10.1111","volume":"36","author":[{"given":"M.","family":"Zandvliet","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Teske","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Chapuis","sequence":"additional","affiliation":[{"name":"AB Science S.A Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fink\u2010Gremmels","sequence":"additional","affiliation":[{"name":"IRAS Veterinary Pharmacology, Pharmacotherapy and Toxicology, Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Schrickx","sequence":"additional","affiliation":[{"name":"IRAS Veterinary Pharmacology, Pharmacotherapy and Toxicology, Faculty of Veterinary Medicine Utrecht University Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-009-9231-6"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1996.tb02080.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.53.082901.103929"},{"key":"e_1_2_5_5_1","first-page":"48","article-title":"Multidrug resistance in cancer: role of ATP\u2010dependent transporters. Nature reviews","volume":"2","author":"Gottesman M.M.","year":"2002","journal-title":"Cancer"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0190.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.71.11.1354"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00383.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-345595"},{"key":"e_1_2_5_10_1","first-page":"6635","article-title":"Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP\u2010overexpressing cells","volume":"61","author":"Honjo Y.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0531.2009.01382.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.03.012"},{"key":"e_1_2_5_13_1","first-page":"1727","article-title":"Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+\u00a0 peripheral blood cells","volume":"4","author":"Kolk D.M.","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U"},{"key":"e_1_2_5_15_1","doi-asserted-by":"crossref","first-page":"27807","DOI":"10.1016\/S0021-9258(18)46856-1","article-title":"The MRP gene encodes an ATP\u2010dependent export pump for leukotriene C4 and structurally related conjugates","volume":"269","author":"Leier I.","year":"1994","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.58.469"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(00)00097-X"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024612"},{"key":"e_1_2_5_19_1","first-page":"393","article-title":"Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo","volume":"18","author":"Steingold S.F.","year":"1998","journal-title":"Anticancer Research"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2011.01.001"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104753"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01849.x"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12039","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12039","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:00:11Z","timestamp":1696244411000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/jvp.12039"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12039","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}